Intended for healthcare professionals

CCBYNC Open access

Rapid response to:

Research

Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study

BMJ 2020; 368 doi: https://doi.org/10.1136/bmj.l6802 (Published 21 January 2020) Cite this as: BMJ 2020;368:l6802

Linked Editorial

Blindsided: challenging the dogma of masking in clinical trials

Linked Analysis

Fool’s gold? Why blinded trials are not always best

Rapid Response:

Re: Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study

Dear Editor,

The problem is that this kind of study can't really capture the bias introduced by not blinding. It looks at average effects across studies, where the bias may actually go in different directions in different studies and thus cancelling out. Imagine a poorly blinded homeopathy study. If performed by proponents of homeopathy, the bias will increase the reported effects; if performed by sceptics, the bias will decrease the reported effects. If performance bias is present, non-blinding may cause additional co-interventions in the control group, leading to decreased treatment effects, whereas for subjective outcomes the effect of measurement bias may be opposite.

Competing interests: No competing interests

24 January 2020
Jos Kleijnen
Systematic reviewer
Professor of Systematic Reviews in Health Care at Maastricht University, the Netherlands
Kleijnen Systematic Reviews Ltd, 6 Escrick Business Park, Riccall Road, Escrick, YO19 6FD, UK